ArticleMovement disorders : official journal of the Movement Disorder Society2013
Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease.
Article in Movement disorders : official journal of the Movement Disorder Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Changes of cerebrospinal fluid AβNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Pooled it
- The role ofFrontiers in neuroscience · 2025Review
- Tau: a biomarker of Huntington's disease.Molecular psychiatry · 2023Review
- CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment.NPJ Parkinson's disease · 2023Article
- Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors.Behavioral sciences (Basel, Switzerland) · 2021Review
- Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson's Disease.Frontiers in aging neuroscience · 2021Article
- A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies.Diagnostics (Basel, Switzerland) · 2020Article
- An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.Neurobiology of disease · 2019Article
- Aβ42/Aβ40 and Aβ42/Aβ38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease: A Pilot Study.Journal of Alzheimer's disease : JAD · 2018Article
- Impaired synaptic function is linked to cognition in Parkinson's disease.Annals of clinical and translational neurology · 2017Article
- Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease.Neurobiology of aging · 2017Article
- Cognitive decline in Parkinson disease.Nature reviews. Neurology · 2017Review
- Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study.NPJ Parkinson's disease · 2016Article
- Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2015Article
- Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population.Parkinson's disease · 2015Article
- Article
- Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.Frontiers in cellular neuroscience · 2014Review
- Mice deficient in transmembrane prostatic acid phosphatase display increased GABAergic transmission and neurological alterations.PloS one · 2014Article
- Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.Nature reviews. Neuroscience · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
Abstract
ParkWest is a large Norwegian multicenter study of newly diagnosed drug-naïve subjects with Parkinson's disease (PD). Cognitively normal PD subjects (PDCN) and PD subjects with mild cognitive impairment (PDMCI) from this cohort have significant hippocampal atrophy and ventricular enlargement, compared to normal controls. Here, we aimed to investigate whether the same structural changes are associated with cerebrospinal fluid (CSF) levels of amyloid beta (Aβ)38 , Aβ40 , Aβ42 , total tau (t-tau), and phosphorylated tau (p-tau). We performed three-dimensional radial distance analyses of the hippocampi and lateral ventricles using the MRI data from ParkWest subjects who provided CSF at baseline. Our sample consisted of 73 PDCN and 18 PDMCI subjects. We found significant associations between levels of all three CSF Aβ analytes and t-tau and lateral ventricular enlargement in the pooled sample. In the PDCN sample, all three amyloid analytes showed significant associations with the radial distance of the occipital and frontal horns of the lateral ventricles. CSF Aβ38 and Aβ42 showed negative associations, with enlargement in occipital and frontal horns of the lateral ventricles in the pooled sample, and a negative association with the occipital horns in PDMCI. CSF Aβ levels in early PD correlate with ventricular enlargement, previously associated with PD dementia. Therefore, CSF and MRI markers may help identify PD patients at high risk for developing cognitive decline and dementia in the course of their illness. Contrary to Alzheimer's disease, we found no associations between CSF t-tau and p-tau and hippocampal atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.